Recurrent Adult Diffuse Large Cell Lymphoma (DBCOND0028497)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00489203	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer	Beclomethasone dipropionate Methotrexate Tacrolimus	supportive_care	2	completed
NCT01233921	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	Palifermin	supportive_care	Not Available	completed
NCT01748721	MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma	Ontuxizumab	treatment	1	completed
NCT00082784	Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms	Alvocidib Bortezomib	treatment	1	completed
NCT01116154	Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	Lenalidomide Vorinostat	treatment	1	terminated
NCT00006251	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT00890747	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	Sunitinib	treatment	1	completed
NCT00293345	3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma	Gemcitabine Triapine	treatment	1	completed
NCT01258998	Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma	No drug interventions	treatment	2	completed
NCT01722305	Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma	Dexamethasone Pomalidomide	treatment	1	completed
NCT00054483	Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction	Bortezomib Bortezomib D-mannitol	basic_science	1	completed
NCT00608361	Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery	Dasatinib	treatment	1	completed
NCT01045928	Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Lenalidomide Rituximab	treatment	1	terminated
NCT01129193	AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma	AR-42	treatment	1	completed
NCT01177371	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma	Busulfan Cyclophosphamide Cyclosporine Methotrexate Methylprednisolone Methylprednisolone hemisuccinate	treatment	2	completed
NCT00110071	Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma	Fludarabine	treatment	1	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT00354185	PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma	Belinostat Tanespimycin	treatment	1	terminated
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT01278615	Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma	Selumetinib	treatment	2	terminated
NCT00131937	Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma	Sorafenib	treatment	2	completed
NCT00118352	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00003970	Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma	Irinotecan	treatment	1	completed
NCT02685670	Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma	Cyclophosphamide Fludarabine	treatment	1 / 2	unknown_status
NCT01479842	Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma	Bendamustine Ibrutinib Rituximab Tyrosine	treatment	1	active_not_recruiting
NCT00002649	Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma	Aldesleukin Cyclophosphamide Etoposide Filgrastim	treatment	3	completed
NCT01815749	Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma	No drug interventions	treatment	1	active_not_recruiting
NCT00073918	Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Cyclophosphamide Etoposide	treatment	2	completed
NCT00058019	Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma	Ixabepilone Patupilone	treatment	2	completed
NCT02240719	Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer	Bendamustine Everolimus	treatment	1	completed
NCT01839916	Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Therapeutic allogeneic lymphocytes	treatment	2	completed
NCT00078858	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT01475058	CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant	Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes	treatment	1 / 2	completed
NCT00014235	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT01093586	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Cyclosporine Methylprednisolone Methylprednisolone hemisuccinate Mycophenolate mofetil	treatment	2	completed
NCT00003166	Bryostatin and Vincristine in B-Cell Malignancies	Bryostatin 1 Sulfate ion Vincristine	treatment	1	completed
NCT01686165	Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL	Belinostat Rituximab	treatment	2	completed
NCT01158274	RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors	Capecitabine RG-4733	treatment	1	completed
NCT01529827	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Fludarabine Melphalan Methotrexate Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00089076	MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma	Ipilimumab	treatment	1 / 2	terminated
NCT03185494	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22	No drug interventions	treatment	1 / 2	unknown_status
NCT00098891	MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas	Entinostat Isotretinoin	treatment	1	completed
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT01864889	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19	No drug interventions	treatment	Not Available	unknown_status
NCT00010192	Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer	Aldesleukin Rituximab	treatment	1	completed
NCT00101244	SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	Ispinesib	treatment	1	terminated
NCT00086944	Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma	Carboplatin Etoposide Filgrastim Ifosfamide Pegfilgrastim Rituximab	treatment	1 / 2	completed
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	Deferasirox	supportive_care	2	terminated
NCT01735604	Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy	No drug interventions	treatment	1 / 2	unknown_status
NCT00049504	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00060372	Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer	Ipilimumab Therapeutic allogeneic lymphocytes	treatment	1	completed
NCT00891072	Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Carboplatin Isosorbide Paclitaxel	treatment	1	completed
NCT01434472	High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma	Cyclosporine Fludarabine Mycophenolate mofetil Rituximab	treatment	2	terminated
NCT00064246	Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder	Ibritumomab tiuxetan Rituximab	treatment	1 / 2	completed
NCT00040846	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00060112	Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma	Gemcitabine	treatment	1	terminated
NCT00003210	Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease	Edodekin alfa Natural Killer Cell	treatment	2	completed
NCT02652910	Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma	No drug interventions	treatment	1 / 2	unknown_status
NCT00017381	Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	Cyclophosphamide Filgrastim Rituximab	treatment	0	completed
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Lithium carbonate	supportive_care	Not Available	completed
NCT01719250	Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Buparlisib	treatment	0	completed
NCT01523223	Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies	Therapeutic allogeneic lymphocytes	treatment	1	completed
NCT00019708	Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	Tanespimycin	treatment	1	terminated
NCT01678443	Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies	Indium Yttrium Y-90	treatment	1	terminated
NCT01408043	Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma	Etoposide Filgrastim Plerixafor	treatment	Not Available	terminated
NCT01075321	Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma	Everolimus Lenalidomide	treatment	1 / 2	completed
NCT01326702	Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors	Bendamustine Rituximab Veliparib	treatment	1 / 2	completed
NCT02281279	Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma	Lenalidomide Rituximab Romidepsin	treatment	1 / 2	withdrawn
NCT00538187	Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma	Bortezomib Bortezomib D-mannitol Obatoclax	treatment	1	terminated
NCT00918333	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma	Everolimus Panobinostat	treatment	1 / 2	completed
NCT00303953	PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma	Belinostat	treatment	2	completed
NCT01959477	Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant	Busulfan Cyclophosphamide Etoposide	treatment	0	completed
NCT01261247	Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Panobinostat	treatment	2	completed
NCT01044745	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Rituximab Tacrolimus	treatment	2	terminated
NCT00343798	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT00058305	Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation	Bryostatin 1 Sulfate ion Vincristine	treatment	2	completed
NCT00096005	Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas	Bortezomib Bortezomib D-mannitol Tanespimycin	treatment	1	terminated
NCT01812005	Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Alisertib Rituximab	treatment	2	terminated
NCT00799461	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	No drug interventions	supportive_care	3	completed
NCT01769911	Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma	6-O-benzylguanine Carmustine Cytarabine Etoposide Melphalan	treatment	Not Available	withdrawn
NCT00089011	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00499811	Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction	Vorinostat	treatment	1	completed
NCT00089271	17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas	Alvespimycin	treatment	1	completed
NCT00856388	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Fludarabine Melphalan	treatment	Not Available	completed
NCT00769288	FAU in Treating Patients With Advanced Solid Tumors or Lymphoma	No drug interventions	treatment	1	completed
NCT02168907	CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Bendamustine Devimistat Lipoic acid Rituximab	treatment	1	terminated
NCT02721407	Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients	No drug interventions	treatment	1	unknown_status
NCT02037256	Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma	Bortezomib Bortezomib D-mannitol Filgrastim	treatment	Not Available	completed
NCT00348985	PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas	Belinostat Bortezomib Bortezomib D-mannitol	treatment	1	completed
NCT01588015	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	1	completed
NCT03097770	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20	No drug interventions	treatment	1 / 2	completed
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Filgrastim Plerixafor	treatment	Not Available	terminated
NCT00118170	Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	Sorafenib	treatment	1	completed
NCT00601718	Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	Carboplatin Etoposide Ifosfamide Rituximab Vorinostat	treatment	1 / 2	completed
NCT01658319	Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies	Fludarabine Methoxyamine	treatment	1	completed
NCT00004241	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma	Tanespimycin	treatment	1	completed
NCT02109224	Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection	Ibrutinib	treatment	1	terminated
NCT00109824	Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	2'-Deoxycytidine Decitabine Valproic acid	treatment	1	completed
NCT00392496	Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma	Sunitinib	treatment	2	completed
NCT00003196	Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma	Cyclosporine Mycophenolate mofetil Therapeutic allogeneic lymphocytes	treatment	Not Available	completed
NCT01110135	Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma	Bendamustine Dexamethasone Etoposide Filgrastim	treatment	2	completed
NCT00054639	Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma	Rituximab	treatment	2	completed
NCT01769222	Ipilimumab and Local Radiation for Selected Solid Tumors	Ipilimumab	treatment	1	terminated
NCT01029366	CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy	Tisagenlecleucel	treatment	1	completed
NCT01273766	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies	Deferasirox	supportive_care	2	completed
NCT00383565	FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Romidepsin	treatment	2	terminated
NCT00278382	Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma	Sorafenib	treatment	2	completed
NCT00458731	Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	Bevacizumab Cediranib	treatment	1	completed
NCT00006473	Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Oxaliplatin	treatment	2	completed
NCT00016094	S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma	Bevacizumab	treatment	2	completed
NCT01397591	Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma	Bortezomib Bortezomib D-mannitol Ofatumumab	treatment	2	terminated
NCT00275080	Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia	2'-Deoxycytidine Decitabine Vorinostat	treatment	1	completed
NCT00438880	Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma	Agatolimod Rituximab	treatment	1 / 2	completed
NCT00867529	Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma	Rituximab	treatment	2	completed
NCT00119392	Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Cyclosporine Fludarabine Mycophenolate mofetil Rituximab	treatment	2	completed
NCT02303392	Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma	Escitalopram Ibrutinib Selinexor	treatment	1	unknown_status
NCT00086840	CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	Menthol Temsirolimus	treatment	2	terminated
NCT00288067	Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Fenretinide Rituximab	treatment	1 / 2	terminated
NCT00536601	High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors	Busulfan Carboplatin Carmustine Cyclophosphamide Etoposide Melphalan Thiotepa	treatment	Not Available	completed
NCT00105001	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Sirolimus Tacrolimus	treatment	2	completed
NCT00290472	CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	Menthol Temsirolimus	treatment	2	completed
NCT00103272	17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer	Bortezomib Bortezomib D-mannitol Tanespimycin	treatment	1	terminated
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	Ondansetron	supportive_care	2	completed
NCT01165112	Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma	Bendamustine Carboplatin Etoposide Rituximab	treatment	1 / 2	completed
NCT01427881	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Busulfan Cyclophosphamide Cyclosporine Fludarabine	treatment	2	completed
NCT01419795	Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant	Lenalidomide Rituximab	treatment	2	terminated
NCT00072514	Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies	Carboplatin Dexamethasone Gemcitabine Rituximab	treatment	2	completed
NCT01652014	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	withdrawn
NCT01789255	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies	Cyclosporine Methotrexate Tacrolimus Vorinostat	supportive_care	2	completed
NCT00077155	Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma	Cilengitide	treatment	1	completed
NCT00112723	Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma	Alvocidib	treatment	1 / 2	terminated